Skip to main content

New procedures for harm reduction prescriptions


Feb 9, 2022

​The foll​​owi​ng i​nformation has been adapted from the BC PharmaCare Newsletter Edition 22-001, published on January 05, 2022.

Note the BCCNM scope of practice for nurse practitioners was amended Jan. 3, 2022, to  include prescribing of pharmaceutical alternatives for safer supply.​

​Prescribers and pharmacists are asked to add “SA” (safer alternative) to prescriptions and PharmaNet entries for prescribed harm reducti​​on drugs. This will improve data for safer supply programs and identify unintended risks or harms.

Most prescribed alternatives to the toxic, illicit drug supply are also used for other indications (e.g., pain). Identifying prescriptions as SA ​​allows programs run by the BC Centre on Substance Abuse, the Ministry of Mental Health and Addiction, and the Ministry of Health to monitor, evaluate, and better mitigate the opioid public health emergency.

Instructions for​​ prescribers

When writing a prescription for a drug to be used as an alternative to the toxic street supply (i.e., for risk mitigation during the dual public health emergencies or as a safer supply option), clearly add “SA” at the bottom of the Directions for Use section of the BC Controlled Prescription form. (See example)

“SA” tells the dispensing pharmacist to tag the prescription with a (non-public) identifying code, for program evaluation purposes, in PharmaNet.


Included drugs​

The most common drugs prescribed for harm reduction are listed below, but all drugs prescribed for harm reduction should be identified with the “SA” code.

Opi​oids (​​not nece​ssarily part of official OAT)

  • Fentanyl patches, tablets, and inhalable compounded options
  • Hy​​dromorphone tablets, injectables, and inhalable compounded options, except when prescribed as part of a formal iOAT, or TiOAT treatment program
  • Morphine injectable, and immediate or sustained release tablets/capsules, except w​hen prescribed for OAT
  • Oxycodone immediate and sustained release formulations​
  • Sufentanil injection
  • Diacetylmorphine (DAM)*

*Currently DA​M is not part of harm reduction programs. If any form (e.g., inhalable compounded options, injectable) becomes available for harm reduction, the prescriptions should include the SA code, which should be entered with each fill/part fill.​​​​

Stimulants

  • Dextroamphetamine IR or SR
  • Methylphenidate IR or SR
  • Any other stimulants prescribed for harm reduction, either commercial or compounded​

​Benzodiaz​​epines​​​

  • Diazepam
  • Clonazepam
  • Any other benzodiazepines prescribed for harm reduction, either commercial or compounded​

900 – 200 Granville St
Vancouver, BC  V6C 1S4
Canada

info@bccnm​.ca
604.742.6200​
​Toll-free 1.866.880.7101 (within Canada only) ​


We acknowledge the rights and title of the First Nations on whose collective unceded territories encompass the land base colonially known as British Columbia. We give specific thanks to the hən̓q̓əmin̓əm̓ speaking peoples the xʷməθkʷəy̓əm (Musqueam) and sel̓íl̓witulh (Tsleil-Waututh) Nations and the Sḵwx̱wú7mesh-ulh Sníchim speaking Peoples the Sḵwx̱wú7mesh Úxwumixw (Squamish Nation), on whose unceded territories BCCNM’s office is located. We also give thanks for the medicines of these territories and recognize that laws, governance, and health systems tied to these lands and waters have existed here for over 9000 years.

We also acknowledge the unique and distinct rights, including rights to health and wellness, of First Nations, Métis, and Inuit peoples from elsewhere in Canada who now live in British Columbia. As leaders in the settler health system, we acknowledge our responsibilities to these rights under international, national, and provincial law.​